77V.F Jacobio Pharmaceuticals Group Co., Ltd.

Healthcare Biotechnology Frankfurt Exchange
0.5250 EUR
Close of Nov 11, 2026
0.4220 0.9550
Market cap
EUR 411M
P/E
6.6x
P/B
2.22x
ROE
-18.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 77V.F undervalued?

Graham number
Price0.5250
Graham value0.6527
Discount19.6%

77V.F trades 19.6% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jacobio Pharmaceuticals Group Co., Ltd. fundamental analysis

No fundamental analysis for Jacobio Pharmaceuticals Group Co., Ltd. yet.

Jacobio Pharmaceuticals Group Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhi…

Full company profile